Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
140 patients have been recruited at sites in Spain, Italy, France and United Kingdom.The open readout of the trial is expected by late 2024.Laminar aims to
United States United Kingdom Pablo Escrib Clinical Operations At Laminar Pharmaceuticals Health Solutions Laminar Pharmaceuticals Sa
Source: thailand-business-news.com